Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PLx Pharma : to Discuss 2021 Second Quarter Financial Results on August 6, 2021 Conference Call and Provide Business Update

07/22/2021 | 04:30pm EDT

SPARTA, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), announced today that the Company will release its 2021 second quarter financial results on Friday, August 6, 2021, before the U.S. financial markets open.

Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

DateFriday, August 6, 2021
Time8:30 a.m. ET
Toll free (U.S.)(866) 394-2901
International
Conference ID
(616) 548-5567
8277376
Webcast (live and replay)www.plxpharma.com under the ‘Investor Relations’ section.

A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 8277376. The archived webcast will be available for 30 days via the aforementioned URL.

About VAZALORE

VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.

About PLx Pharma Inc.

PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com


Primary Logo

Source: PLx Pharma Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about PLX PHARMA INC.
09/21PLX PHARMA : BWS Financial Initiates Coverage on PLx Pharma With Buy Rating, $29 Price Tar..
MT
09/21PLX PHARMA : Corporate Presentation
PU
09/21PLX PHARMA INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/09PLX PHARMA : to Present at Upcoming Virtual Healthcare Industry Conferences
AQ
08/26PLX PHARMA : Announces Nationwide Rollout of Aspirin Capsules
MT
08/26PLX PHARMA : VAZALORE™ Now on Shelves; National Media Campaign Launches Today
AQ
08/06PLX PHARMA INC. : Entry into a Material Definitive Agreement, Financial Statements and Exh..
AQ
08/06PLX PHARMA : Q2 Loss Widens
MT
08/06PLX PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP..
AQ
08/06Plx Pharma Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
More news
Analyst Recommendations on PLX PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 9,34 M - -
Net income 2021 -48,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,28x
Yield 2021 -
Capitalization 479 M 479 M -
Capi. / Sales 2021 51,2x
Capi. / Sales 2022 14,6x
Nbr of Employees 10
Free-Float 89,5%
Chart PLX PHARMA INC.
Duration : Period :
PLx Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLX PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 17,80 $
Average target price 24,00 $
Spread / Average Target 34,8%
EPS Revisions
Managers and Directors
Natasha Giordano President, Chief Executive Officer & Director
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain
Michael J. Valentino Executive Chairman
Gary S. Balkema Independent Director
Kirk K. Calhoun Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PLX PHARMA INC.222.46%479
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.35.75%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202